Stuart A. Lipton
The Burnham Institute for Medical Research
The Salk Institute for Biological Studies
The Scripps Research Institute
and the University of California--San Diego
USA
Name/email consistency: high
- Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Lipton, S.A. Curr. Drug. Targets (2007)
- Pathologically activated therapeutics for neuroprotection. Lipton, S.A. Nat. Rev. Neurosci. (2007)
- Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Lipton, S.A. Nat. Rev. Drug. Discov (2006)
- The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Lipton, S.A. Current. Alzheimer. Research (2005)
- Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function". Lipton, S.A., Nakamura, T., Yao, D., Shi, Z.Q., Uehara, T., Gu, Z. Science (2005)
- Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Lipton, S.A. J. Alzheimers Dis. (2004)
- Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Lipton, S.A. NeuroRx (2004)
- Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Lipton, S.A., Choi, Y.B., Takahashi, H., Zhang, D., Li, W., Godzik, A., Bankston, L.A. Trends Neurosci. (2002)
- Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Lipton, S.A., Bossy-Wetzel, E. Cell (2002)
- Retinal ganglion cells, glaucoma and neuroprotection. Lipton, S.A. Prog. Brain Res. (2001)